TB-500: Why FDA Evaluated It for Wound Healing

TB-500 is sometimes promoted for wound repair, but it has not been shown in human clinical trials to heal wounds. FDA evaluated the peptide in 2026 because it had been nominated for possible compounded use in wound healing—not because FDA had established that it was safe or effective.

The distinction matters. FDA identified no studies in which TB-500 was administered to people for wound healing or any other purpose. Research involving the larger protein thymosin beta-4 cannot automatically be treated as evidence for TB-500 because the two substances are not the same.

What Is TB-500?

TB-500 is a synthetic seven-amino-acid peptide corresponding to amino acids 17 through 23 of thymosin beta-4. Thymosin beta-4 is a naturally occurring 43-amino-acid protein involved in cellular processes that include actin binding, cell movement, and tissue responses to injury.

The short sequence in TB-500 is sometimes described as an “active region” of thymosin beta-4. That description does not establish that the fragment reproduces the larger protein's effects in a living person. Shortening a protein can change its shape, stability, distribution, metabolism, receptor interactions, immune effects, and biological activity.

Within the wider peptide therapy evidence base, the precise substance studied is fundamental. A paper about full-length thymosin beta-4 is not a clinical trial of TB-500.

Why Did FDA Evaluate TB-500 for Wound Healing?

TB-500 acetate was nominated for possible inclusion on the Section 503A Bulks List for wound healing. The nomination proposed subcutaneous and intramuscular administration but did not define a specific type of wound.

FDA's 2026 TB-500 briefing document evaluated the substance's physical and chemical characterization, proposed use, available evidence, safety information, historical use in compounding, and whether approved therapies already address the condition.

“Wound healing” is a broad category rather than one diagnosis. A clean surgical incision, burn, pressure injury, diabetic foot ulcer, infected wound, vascular ulcer, and corneal injury have different causes, treatment standards, and clinical endpoints. Without a defined wound type, population, formulation, dose, and route, it is difficult to determine what benefit a proposed therapy is supposed to provide.

Why Is Thymosin Beta-4 Research Often Confused With TB-500 Research?

Much of the scientific rationale cited around TB-500 comes from experiments involving thymosin beta-4. Researchers have studied the full-length protein in cell, animal, and some human settings, including specialized eye and wound-related products.

Those findings may help explain why researchers are interested in related sequences, but they cannot prove that TB-500 has the same properties. FDA's review treated evidence involving full-length thymosin beta-4 as indirect evidence, not direct proof of TB-500 effectiveness.

This is an important evidence rule: results belong to the molecule, formulation, route, dose, and population that were actually tested. Similar names and shared amino-acid sequences do not make two products interchangeable.

What Direct Evidence Did FDA Find for TB-500?

FDA found very little direct evidence. The agency did not identify adequate animal studies showing that TB-500 improved wound healing in vivo. It also found no clinical studies administering TB-500 to humans by any route.

One laboratory study assessed TB-500 free base and related metabolites in a scratch assay using human skin fibroblasts. In that experiment, TB-500 free base did not induce healing activity at the tested concentration, although one metabolite showed activity in vitro.

A scratch assay is a laboratory model in which researchers create a gap in a layer of cultured cells and observe cell movement into that space. It can help screen biological hypotheses, but it is not an open wound and does not reproduce blood flow, infection, immune response, nerve function, tissue depth, or other factors that affect healing in a patient.

The negative finding for TB-500 in that assay does not prove the peptide could never affect any wound-related process. It does mean the study cannot be cited as evidence that TB-500 heals wounds.

Has TB-500 Been Studied in People?

FDA did not identify human clinical studies in which TB-500 was administered for wound healing or another medical purpose. That means there is no established human evidence for a clinically meaningful dose, route, treatment duration, benefit, pharmacokinetic profile, or monitoring plan.

Human evidence for thymosin beta-4 does not close this gap. Even if the larger protein showed an effect in a particular formulation, a separate development program would be needed to establish whether TB-500 reaches the relevant tissue, remains stable, produces the intended activity, and has an acceptable safety profile.

Testimonials, before-and-after images, animal studies, and product descriptions are not substitutes for controlled human trials.

What Would a Useful Human Study Need to Show?

A meaningful trial would start with a clearly characterized TB-500 product and a specific wound type. It would compare TB-500 plus established care with an appropriate control, use prespecified outcomes, and track adverse events.

Depending on the condition, relevant outcomes might include:

• Time to complete and durable wound closure
• Change in wound area measured with a validated method
• Infection, hospitalization, or need for surgery
• Pain and function
• Recurrence after apparent closure
• Serious and treatment-related adverse events

The study would also need enough participants and follow-up to distinguish a treatment effect from normal healing, differences in standard care, and measurement error.

What Are the Safety and Product-Quality Gaps?

The absence of human exposure studies leaves basic safety questions unanswered. Common adverse effects, serious risks, immune reactions, interactions, contraindications, systemic exposure, and long-term effects are not established.

FDA also identified product-characterization concerns relevant to peptide bulk substances. Peptides can aggregate or contain synthesis-related impurities. Those features can alter potency and may increase immune risk. Manufacturing controls, sterility, identity, purity, concentration, storage, and stability are particularly important when a product is proposed for injection or use around damaged tissue.

A label such as “research use only” does not establish pharmaceutical quality or make a product appropriate for human use.

What Did PCAC Recommend in 2026?

At its July 2026 meeting, the Pharmacy Compounding Advisory Committee—PCAC—recommended that TB-500 acetate be considered for inclusion on the Section 503A Bulks List. The FDA meeting page lists wound healing as the use evaluated.

That recommendation was advisory. It did not:

• Approve TB-500 as a drug
• Prove that TB-500 heals wounds
• Establish an approved dose, route, or formulation
• Make every marketed TB-500 product lawful or safe
• By itself place TB-500 acetate on the final 503A Bulks List

FDA staff had recommended against adding TB-500 acetate based on the available evidence, safety, characterization, and need factors. The committee's recommendation and FDA staff's analysis are separate parts of the process. FDA retains final authority, and the current regulatory status should be verified immediately before publication.

Why Established Wound Care Still Matters

Good wound care depends on the cause. Treatment may include cleaning, pressure relief, circulation assessment, glucose management, infection treatment, debridement, moisture control, dressings, or surgery. A peptide cannot substitute for identifying poor blood flow, neuropathy, infection, repeated pressure, or another problem preventing repair.

Waiting on an unproven product can delay effective treatment. Increasing redness, warmth, swelling, drainage, odor, pain, fever, black tissue, loss of sensation, an exposed deep structure, or a wound that is not improving warrants evaluation by an appropriately licensed clinician.

Frequently Asked Questions

Does TB-500 heal wounds?

It has not been established. FDA found no human clinical studies of administered TB-500 and no adequate in vivo evidence showing that it heals wounds.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a seven-amino-acid fragment, while thymosin beta-4 is a 43-amino-acid protein. Evidence for the full-length protein cannot automatically be attributed to the fragment.

Did FDA approve TB-500 for wound healing?

No. PCAC recommended that TB-500 acetate be considered for inclusion on the 503A Bulks List. That advisory recommendation was not FDA approval and did not establish effectiveness.

Was TB-500 tested in humans?

FDA's 2026 review identified no clinical studies in which TB-500 was administered to humans by any route.

Can TB-500 replace standard wound care?

No evidence supports replacing established wound evaluation or treatment with TB-500. Delayed care can be dangerous, especially for infected, diabetic, vascular, deep, or nonhealing wounds.

Key Takeaway

FDA evaluated TB-500 because it was nominated for possible compounded use in wound healing. The evaluation did not find human trials establishing that TB-500 heals wounds, and evidence involving full-length thymosin beta-4 cannot be treated as direct evidence for the shorter peptide.

The most accurate conclusion is that TB-500 remains an experimental substance with substantial evidence, safety, and product-quality gaps. A well-characterized product and controlled human trials in clearly defined wound types would be needed to establish benefit, risks, dosing, and monitoring.

This article is for educational purposes and is not medical advice. Medical decisions should be made with an appropriately licensed clinician.